Synthesis, activity, and molecular modeling of new 2,4-dioxo-5- (naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors

Journal of Medicinal Chemistry

Volumn 41, Issue 24, 1998, Pages 4706-4715

  Fresneau, Patrick ^a   Cussac, Max ^a   Morand, Jean Marc ^a   Szymonski, Barbara ^a   Tranqui, Duc ^b   Leclerc, Gérard ^a  

^a Laboratoire de Pharmacochimie   (France)

^b LABORATOIRE DE CRISTALLOGRAPHIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIOXO 5 (NAPHTHYLMETHYLENE) 3 THIAZOLIDINEACETIC ACID DERIVATIVE; 4 OXO 2 THIOXO 5 (2 NAPHTHYLMETHYLENE) 3 THIAZOLIDINEACETIC ACID DERIVATIVE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; PONALRESTAT; UNCLASSIFIED DRUG; ZOPOLRESTAT;

ANIMAL TISSUE; ARTICLE; CATARACT; CATTLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DRUG ACTIVITY; DRUG CONFORMATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; LENS; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ACETIC ACIDS; ALDEHYDE REDUCTASE; ANIMALS; BENZOTHIAZOLES; CATTLE; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; LENS, CRYSTALLINE; MODELS, MOLECULAR; PHTHALAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 0032548075     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9801399     Document Type: Article

References (56)

1. Kinoshita, J. H.; Merola, L. O.; Satoh, K.; Dikmak, E. Osmotic changes caused by the accumulation of dulcitol in the lenses of rats fed with galactose. Nature 1962, 194, 1085-1087.
2. Gabbay, K. H.; O'Sullivan, J. B. The sorbitol pathway: enzyme localization and content in normal and diabetic nerve and cord Diabetes 1968, 17, 239-243.
3. Kinoshita, J. H. Cataracts in galactosemia. Invest. Ophthalmol. 1965, 4 (5), 786-799.
4. Kinoshita, J. H.; Dvornik, D.; Kraml, M.; Gabbay, K. H. The effects of an aldose reductase inhibitor on galactose-exposed rabbit lens. Biochim. Biophys. Acta 1968, 158, 472-475.
5. Gabbay, K. H. Hyperglycemia, polyol metabolism and complications of diabetes mellitus. Annu. Rev. Med. 1975, 26, 521-536.
6. Dvornik, D. Chronic complications of diabetes. Annu. Rep. Med. Chem. 1978, 13, 159-166.
7. Robison, W. G.; Kador, P. F.; Kinoshita, J. H. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science 1983, 221, 1177-1179.
8. Lipinski, C. A.; Hutson, N. J. Aldose reductase inhibitors as a new approach to the treatment of diabetic complications. Annu. Rep. Med. Chem. 1984, 19, 169-177.
9. Cogan, D. G.; Kinoshita, J. H.; Kador, P. F.; Robison, W. G.; Datiles, M. B.; Cobo, L. M.; Kupfer, C. NIH conference. Aldose reductase and complications of diabetes. Ann. Intern. Med. 1984, 101 (1), 82-91.
10. Kador, P. F.; Robison, W. G.; Kinoshita, J. H. The pharmacology of aldose reductase inhibitors. Annu. Rev. Pharmacol. Toxiool. 1985, 25, 691-714.
11. Tomlinson, D. R.; Willars, G. B.; Carrington, A. L. Aldose reductase inhibitors and diabetic complications. Pharmacol. Ther. 1992, 54 (2), 151-194.
12. Kador, P. F.; Kinoshita, J. H.; Sharpless, N. E. Aldose-reductase inhibitors: a new class of agents for the pharmacological control of certain diabetic complications. J. Med. Chem. 1985, 28, 841-849.
13. Humber, L. G. The medicinal chemistry of aldose reductase inhibitors. Prog. Med. Chem. 1987, 24, 299-343.
14. Sarges, R. Aldose reductase inhibitors. In Trends in Medicinal Chemistry. Ninth Symposium; Mutschler, E., Winterfeldt, T. E., Eds.; VCH: Basel, 1987; pp 551-564.
15. Kador, P. F. The role of aldose reductase in the development of diabetic complications. Med. Res. Rev. 1988, 8 (3), 325-352.
16. Larson, E. R.; Lipinski, C. A.; Sarges, R. Medicinal chemistry of aldose reductase inhibitors. Med. Res. Rev. 1988, 8 (2), 159-186.
17. Sarges, R. Aldose reductase inhibitors: structure-activity relationships and therapeutic potential. In Advances in Drug Research; Testa, B., Ed.; Academic Press Ltd.: London, 1989; Vol. 18, p 139.
18. Sarges, R.; Oates, P. J. Aldose reductase inhibitors: recent developments. Prog. Drug Res. 1993, 40, 99-161.
19. Kador, P. F.; Sharpless, N. E. Pharmacophore requirements of the aldose reductase inhibitor site. Mol. Pharmacol. 1983, 24 (3), 521-531.
20. Chazeau, V.; Cussac, M.; Boucherle, A. Study of 5-arylidene-2-thiohydantoins with potential immunomodulating and anticancer activities. Eur. J. Med. Chem. 1992, 27 (6), 615-625.
21. Rondeau, J. M.; Tete-Favier, F.; Podjarny, A.; Reymann, J. M.; Barth, P.; Biellmann, J. F.; Moras, D. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase. Nature 1992, 355, 469-472.
22. Wilson, D. K.; Bohren, K. M.; Gabbay, K. H.; Quiocho, F. A. An unlikely sugar substrate site in the 1.65 Å structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science 1992, 257, 81-84.
23. Borhani, D. W.; Harter, T. M.; Petrash, J. M. The crystal structure of the aldose reductase·NADPH binary complex. J. Biol. Chem. 1992, 267 (34), 24841-24847.
24. Wilson, D. K.; Tarle, I.; Petrash, J. M.; Quiocho, F. A. Refined 1.8 Å structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9847-9851.
25. Harrison, D. H.; Bohren, K. M.; Ringe, D.; Petsko, G. A.; Gabbay, K. H. An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate and glucose 6-phosphate. Biochemistry 1994, 33 (8), 2011-2020.
26. Eriguchi, A.; Takegoshi, T. Studies on hypolipidemic agents. I. Synthesis of 1.3-dioxolanes and 1,3-dioxanes. Chem. Pharm. Bull. 1982, 30, 428-439.
27. Lindley, W. A.; McDowell, D. W. H. Keto-enol tautomerism in the thiophene analogues of naphthacen-5-one. J. Org. Chem. 1982, 47, 705-709.
28. Makosza, M.; Owczarczyk, Z. Dihalomethylation of nitroarenes via Vicarious nucleophilic substitution of hydrogen with trihalomethyl carbanions. J. Org. Chem. 1989, 54, 5094-5100.
29. Corey, E. J.; Suggs, J. W. Pyridinium chlorochromate. An efficient reagent for oxidation of primary and secondary alcohols to carbonyl compounds. Tetrahedron Lett. 1975, 31, 2647-2650.
30. Adams, R.; Binder, L. O. Restricted rotation in aryl olefins. III. Preparation and resolution of βchloro-β-(2-methyl-1-naphthyl)-acrylic acids. J. Am. Chem. Soc. 1941, 63, 2773-2775.
31. Danish, A. A.; Silverman, M.; Tajima, Y. A. Dienophilic reactions of aromatic double bonds in the synthesis of β-substituted naphthalenes. J. Am. Chem. Soc. 1954, 76, 6144-6150.
32. 13C NMR. Spectrochim. Acta 1998, in press.
33. 13C nuclear magnetic resonance studies of ethenyl-substituted benzenoid aromatic compounds. Magn. Res. Chem. 1991, 29(1), 2-8.
34. Breitmaier, R. M.; Bassler G. C. Carbon 13 NMR Spectroscopy, 3rd ed.; VCH: Weinheim, 1987; pp 1-515.
35. Voegeli, U.; Von Philipsborn, W.; Nagarajan, K.; Nair, M. D. Structure of addition products of acetylenedicarboxylic acid esters with various dinucleophiles. An application of C, H-spincoupling constants. Helv. Chim. Acta 1978, 61 (2), 607-617.
36. Ishida, T.; In, Y.; Inoue, M.; Ueno, Y.; Tanaka, C.; Hamanaka, N. Structural elucidation of epalrestat (ONO-2235), a potent aldose reductase inhibitor, and isomerization of its double bonds. Tetrahedron Lett. 1989, 30 (8), 959-962.
37. Tranqui, D.; Fresneau, P.; Cussac, M. Crystal structure of (Z)-5-(1-methoxy-2-naphthylmethylidene)-4-oxo-2-thioxothiazolidine-3-yl acetic acid. Acta Crystallogr. 1998, C54, 1152-1154.
38. Kador, P. F.; Sharpless, N. E. Structure-activity studies of aldose reductase inhibitors containing the 4-oxo-4-H-chromen ring system. Biophys. Chem. 1978, 8 (1), 81-85.
39. Ward, W. H. J.; Sennitt, C. M.; Ross, H.; Dingle, A.; Timms, D.; Mirrlees, D. J.; Tuffin, D. P. Ponalrestat: a potent and specific inhibition of aldose reductase. Biochem. Pharmacol. 1990, 39 (2), 337-346.
40. Brittain, D. R. In Proceedings of the Third SCI-RSC Medicinal Chemistry Symposium; Lambert, R. W., Ed.; Royal Society of Chemistry: London, 1986; pp 210-240.
41. Mylari, B. L.; Larson, E. R.; Beyer, T. A.; Zembrowski, W. J.; Aldinger, C. E.; Dee, M. F.; Siegel, T. W.; Singleton, D. H. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[(5-(trifluoromethyl)-2-benzothiazolyl)-methyl]-1- phthalazineacetic acid (zopolrestat) and congeners. J. Med. Chem. 1991, 34, 108-122.
42. Terashima, H.; Hama, K.; Yamamoto, R.; Tsuboshima, M.; Kikkawa, R.; Hatanaka, I.; Shigeta, Y. Effects of a new aldose reductase inhibitor on various tissues in vitro. J. Pharmacol. Exp. Ther. 1984, 229 (1), 226-230.
43. Sestanj, K.; Bellini, F.; Fung, S.; Abraham, N.; Treasurywala, A.; Humber, L.; Simard-Duquesne, N. S.; Dvornik, D. N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N-methylglycine (Tolrestat), a potent, orally, active aldose-reductase inhibitor. J. Med. Chem. 1984, 27, 255-256.
44. Sarges, R.; Peterson, M. J. Sorbinil: a member of the novel class of spirohydantoin aldose reductase inhibitors. Metabolism 1986, 35 (Suppl. 1), 101-104.
45. +/ NADPH and alrestatin-like inhibitors. Biochemistry 1994, 33, 7157-7165.
46. SYBYL 6.1; 1994; Tripos Associates, 1699 S. Hanley Rd, Suite 303, St. Louis, MO 63144.
47. Tarle, I.; Borhani, D. W.; Wilson, D. K.; Quiocho, F. A.; Petrash, J. M. Probing the active site of human aldose reductase. Site-directed mutagenesis of Asp43, Tyr48, Lys77, and His110. J. Biol. Chem. 1993, 268 (34), 25687-25693.
48. Börhen, K. M.; Grimwasch, C. E.; Lai, C. J.; Harrison, D. H.; Ringe, D.; Petsko, G. A.; Gabbay, K. H. Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme. Biochemistry 1994, 33, 2021-2032.
49. Carper, D. A.; Hohman, T. C.; Old, S. E. Residues affecting the catalysis and inhibition of rat lens aldose reductase. Biochim. Biophys. Acta 1995, 1246, 67-73.
50. Bhatnagar, A.; Liu, S. Q.; Ueno, N.; Chakrabarti, B.; Srivastava, S. K. Human placental aldose reductase: role of Cys298 in substrate and inhibitor binding. Biochim. Biophys. Acta 1994, 1205(2), 207-214.
51. Powell, M. J. D. Restart procedures for the conjugate gradient method. Mathematical Programming 1977, 12, 241-254.
52. Morjana, N. A.; Flynn, T. G. Aldose reductase from human psoas muscle: purification, substrate specificity, immunological characterization, and effect drugs and inhibitors. J. Biol. Chem. 1989, 264 (5), 2906-2911.
53. Wermuth, B.; Monder, C. Aldose and aldehyde reductase exhibit isocorticosteroid reductase activity. Eur. J. Biochem. 1983, 131 (2), 423-426.
54. Smith, J. G.; Dibble, P. W.; Sandborn, R. E. The preparation and reactions of Naphtho[1,2-c]furans and naphtho[2,3-c]furans. J. Org. Chem. 1986, 51, 3762-3768.
55. Look, M.; Padgett, W. M.; Hyman, J.; Fenyes, J. G. E.; Lee, H. P. C. 3-Hydroxy-2-naphthoic acid. Chem. Abstr. 1965, 62, 503.
56. Narasimhan, N. S.; Mali, R. S. Synthetic application of lithiation reactions - VII. New synthesis of linear and angular Naphthofurans and Benzocoumarins. Tetrahedron 1975, 31, 1005-1009.